Lofexidine - Britannia Pharmaceuticals

Drug Profile

Lofexidine - Britannia Pharmaceuticals

Alternative Names: BA-168; BritLofex; Lofexidine hydrochloride; LUCEMYRA; MDL-14042; MDL-14042A; RMI-14042A

Latest Information Update: 08 Aug 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Britannia Pharmaceuticals
  • Developer Britannia Pharmaceuticals; Salix Pharmaceuticals; US WorldMeds
  • Class Antihypertensives; Chlorobenzenes; Imidazolines; Phenyl ethers; Small molecules
  • Mechanism of Action Alpha 2 adrenergic receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Opioid abuse

Highest Development Phases

  • Marketed Opioid abuse

Most Recent Events

  • 06 Aug 2018 Launched for Opioid abuse in USA (PO)
  • 26 Jun 2018 Lofexidine is expected to be commercially available in USA in August 2018
  • 25 Jun 2018 Salix And US WorldMeds enter into an exclusive co-promotion agreement for lofexidine in Opioid abuse
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top